IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort

被引：0

作者：

Morfouace, M. ^{[1
]}

Schulz, D. ^{[2
]}

Eling, N. ^{[3
]}

Marzetta, F. ^{[4
]}

Loizides, C. ^{[5
]}

Rusakiewicz, S. ^{[6
]}

Liechti, R. ^{[4
]}

Hong, H. S. ^{[7
]}

Robert, M-S. ^{[8
]}

Bironzo, P. ^{[9
]}

Cufer, T. ^{[10
]}

Oselin, K. ^{[11
]}

Cloarec, N. ^{[12
]}

Oliveira, J. ^{[13
]}

Bodenmiller, B. ^{[14
]}

Besse, B. ^{[15
]}

机构：

[1] Merck KGaA Headquarters Merck Grp, RU Oncol Dept, Darmstadt, Germany

[2] UZH Univ Zurich, Oncol Dept, Irchel Campus, Zurich, Switzerland

[3] UZH Univ Zurich, Oncol Dept, Competence Ctr Personalized Med CC PM, Zurich, Switzerland

[4] SIB Swiss Inst Bioinformat, Oncol Dept, Lausanne, Switzerland

[5] EORTC AISBL IVZW European Org Res & Treatment Can, Oncol Dept, Brussels, Belgium

[6] Ludwig Canc Ctr Univ Lausanne CHUV, Oncol Dept CTE, Lausanne, Switzerland

[7] Merck KGaA, TIP Immunooncol Dept, Darmstadt, Germany

[8] EORTC AISBL IVZW European Org Res & Treatment Can, Project Direct, Brussels, Belgium

[9] Azienda Osped Univ San Luigi Gonzaga, Oncol Dept, Orbassano, Italy

[10] Univ Ljubljana, Med Oncol Dept, Fac Med, Ljubljana, Slovenia

[11] North Estonia Med Ctr Fdn SA Pohja Eesti Regionaa, Chemotherapy Dept, Tallinn, Estonia

[12] CH Henri Duffaut, Oncol, Avignon, France

[13] EPE IPO Porto, Inst Portugues Oncol Porto Francisco Gentil, Oncol Dept, Porto, Portugal

[14] UZH Univ Zurich, Inst Mol Life Sci, Irchel Campus, Zurich, Switzerland

[15] Inst Gustave Roussy, Canc Med Dept, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

基金：

欧盟地平线“2020”;

关键词：

D O I：

10.1016/j.annonc.2023.09.1294

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2266P

引用

页码：S1164 / S1164

页数：1

共 50 条

[21] MOLECULAR MARKERS IN NON-SMALL CELL LUNG CANCER (NSCLC)
Heigener, D.
ANTICANCER RESEARCH, 2011, 31 (05) : 1979 - 1979
[22] CHEMOTHERAPY FOR NON-SMALL CELL LUNG-CANCER (NSCLC)
THATCHER, N
BRITISH JOURNAL OF CANCER, 1987, 56 (06) : 886 - 887
[23] Staging of non-small cell lung cancer (NSCLC): A review
Tsim, S.
O'Dowd, C. A.
Milroy, R.
Davidson, S.
RESPIRATORY MEDICINE, 2010, 104 (12) : 1767 - 1774
[24] Sequential chemotherapy in non-small cell lung cancer (NSCLC)
不详
ANTICANCER RESEARCH, 2005, 25 (6D) : 4831 - 4832
[25] PET/MRI in Non-Small Cell Lung Cancer (NSCLC)
Alorfi, Fawziah
Bomanji, Jamshed
Bertoletti, Linda
Fraioli, Francesco
SEMINARS IN NUCLEAR MEDICINE, 2025, 55 (02)
[26] Personalized Therapy of Non-small Cell Lung Cancer (NSCLC)
Gadgeel, Shirish M.
LUNG CANCER AND PERSONALIZED MEDICINE: NOVEL THERAPIES AND CLINICAL MANAGEMENT, 2016, 890 : 203 - 222
[27] Induction therapy for non-small cell lung cancer (NSCLC)
Nakamura, H
Furukawa, K
Ikeda, N
Shibuya, H
Tanaka, K
Okunaka, T
Hirano, T
Sakai, M
Saito, M
Konaka, C
Kato, H
XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1996, : 1029 - 1033
[28] Integrated Profiling of Advanced Non-Small-Cell Lung Cancer: The EORTC IMMUcan Project - Lung Cohort
Gobbini, E.
Morfouace, M.
Hong, H.
Liechti, R.
Besse, B.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S527 - S527
[29] Oxaliplatin and docetaxel as first line chemotherapy for patients with non-small cell lung cancer (NSCLC).
Santos, ES
Raez, LE
Rocha-Lima, C
Tolba, K
Negret, L
Farfan, N
Decesare, T
Lopes, G
Rosado, MF
Wu, J
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 687S - 687S
[30] Linifanib treatment in patients with non-small cell lung cancer (NSCLC): Phase II results
Soo, R. A.
Goss, G. D.
Salgia, R.
Besse, B.
Gandara, D. R.
Hanna, N. H.
Ricker, J. L.
Qian, J.
Carlson, D. M.
Tan, E.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →